Recent News

A protein on certain immune cells is a promising target for making immunotherapy more effective against breast cancer.

Scientists are dusting off their biochemistry textbooks in the hunt for clues to cancer.

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.

New research on an experimental drug provides hope for better responses to immunotherapy.

Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center (MSK), and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery.

A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.

One of MSK’s leading immunologists turned 60 on Friday, and scientists came to celebrate.

Wondering how cryo-electron microscopy will impact medicine? Hear it from the source.

A surprising finding challenges long-held dogma about how certain immune cells develop into specialized types in diverse tissues.